MAM
BDTX icon

Martingale Asset Management’s Black Diamond Therapeutics BDTX Stock Holding History

Martingale Asset Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,920
Closed -$197K – 807
2021
Q4 		$197K Hold
36,920
– – ﹤0.01% 799
2021
Q3 		$313K Buy
36,920
+6,800
+23% +$67.1K ﹤0.01% 742
2021
Q2 		$368K Buy
+30,120
New +$595K ﹤0.01% 676

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Martingale Asset Management's BDTX Position: Q1 2022 in Review

Martingale Asset Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2022, closing a stake of 36,920 shares — an estimated $197K sold.

Martingale Asset Management first reported a position in BDTX in Q2 2021 and held it in 3 quarters. The position peaked at $368K in Q2 2021. 87 funds tracked by Wall St. Rank hold BDTX as of Q1 2022.

  • Martingale Asset Management reported no remaining Black Diamond Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Martingale Asset Management sold 36,920 Black Diamond Therapeutics shares in Q1 2022, an estimated $197K.
  • Martingale Asset Management first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 3 quarters.
  • Martingale Asset Management's Black Diamond Therapeutics position peaked at $368K in Q2 2021.
  • 87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2022.

Based on Martingale Asset Management's 13F filing for Q1 2022, filed 12 May 2022.